DPC's IMMULITE 1000 Automated Immunoassay System Receives FDA Clearance.

Business Editors

LOS ANGELES--(BUSINESS WIRE)--Oct. 24, 2002

Diagnostic Products Corporation (NYSE:DP) has received FDA 510(k) clearance for the IMMULITE(R) 1000 Automated Immunoassay System and it is now available. The next-generation IMMULITE 1000 is the latest addition to the IMMULITE family of systems. Designed to retain all of the existing strengths of the IMMULITE system, the IMMULITE 1000 has many new features that reduce operator intervention and thereby increase productivity.

"This is terrific news for both DPC and our customers," said Michael Ziering, President and Chief Executive Officer of DPC. "With approximately 6000 IMMULITE systems placed worldwide, it was clear that the system was meeting the needs of many laboratories in a variety of testing environments. The addition of on-board dilutions, Windows(R) 2000 operating software and a consolidated footprint make the IMMULITE 1000 an enhanced platform for the continued expansion of our testing menu, without sacrificing any of the excellent performance characteristics of the original IMMULITE system."

The DPC IMMULITE family of automated immunoassay systems offers customers a solution to their immunoassay testing needs, whether they are large reference labs, hospital labs or physician office labs. The extensive breadth of the test menu, with over 100 assays and 240 different allergens, and the ease of use and reliability of the IMMULITE systems have made them widely accepted throughout the world.

For more information on the automated chemiluminescent IMMULITE immunoassay systems, please call 800/372-1782, fax [phone] or e-mail [e-mail].

Founded in 1971, Diagnostic Products Corporation (DPC) is the global leader dedicated exclusively to immunodiagnostic testing. The Company's product menu includes over 400 tests to measure microorganisms, hormones, drugs and other medically important substances present at infinitesimal concentrations in body fluids and tissues. DPC also designs and manufactures automated laboratory instrumentation which provides fast, accurate results while reducing labor and reagent costs. DPC sells its products to hospitals, clinics and laboratories domestically and in over 100 countries. Additional Company information can be found on the Company's Web site at www.dpcweb.com.

Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially. These factors include the Company's ability to successfully market new and existing products; its dependence on certain suppliers; domestic and foreign government regulation; its ability to keep abreast of technological innovations and to translate them into new products; competition; political and economic instability in certain markets; and other risks and uncertainties disclosed from time to time in the Company's SEC reports and filings.